PDS Biotechnology Corp Retained Earnings
PDS Biotechnology Corp (PDSB) had Retained Earnings of -$233.71 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$233.71M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$223.96M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$216.61M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$209.04M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$233.71M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$223.96M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$216.61M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$209.04M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$200.03M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$190.60M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$182.11M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$174.16M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$163.43M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$155.10M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$144.50M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$133.60M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$122.75M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$111.22M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$101.56M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$82.42M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$75.00M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$69.18M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | -$60.70M 10-K · filed 2023-03-28 | |
| 2021-09-30 | -$54.38M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$47.42M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$46.83M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$43.79M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$39.76M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$35.85M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$32.92M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | -$28.94M 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$23.83M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$18.08M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | -$14.20M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$21.94M 10-K · filed 2020-03-27 | -$192.82M 10-K · filed 2019-02-21 |
| 2018-09-30 | -$189.73M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | -$185.47M 10-Q · filed 2018-08-01 | |
| 2018-03-31 | -$172.79M 10-Q · filed 2018-05-01 | |
| 2017-12-31 | -$151.95M 10-K · filed 2019-02-21 | |
| 2017-09-30 | -$138.04M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | -$126.76M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | -$113.26M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | -$101.07M 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$91.56M 10-Q · filed 2016-11-01 | |
| 2016-06-30 | -$80.80M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | -$71.42M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | -$62.25M 10-K · filed 2017-03-02 | |
| 2015-09-30 | -$54.20M 10-Q · filed 2015-11-06 | |
| 2014-12-31 | -$29.82M 10-K · filed 2016-03-08 | -$29.82M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |